Pfizer (PFE) IV into FDA decision on abrocitinib.
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $26.32 +0.23%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -58.5%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -58.5%
Join SI Premium – FREE
Pfizer (NYSE: PFE) 30-day option implied volatility is at 25; compared to its 52-week range of 17 to 61 into FDA decision on abrocitinib.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- Chipotle Mexican Grill (CMG) call put ratio 1 call to 2.7 puts into quarter results and outlook
- Otis Worldwide (OTIS) May option implied volatility into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
